搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
6 天
默沙东集团的KEYTRUDA在头颈癌试验中显示出前景
新泽西州拉威 - 默沙东集团(NYSE:MRK)宣布了其KEYNOTE-689第三期试验的积极结果。该试验评估了公司的抗PD-1疗法KEYTRUDA作为III期或IVA期切除的局部晚期头颈鳞状细胞癌(LA-HNSCC)患者的围手术期治疗的有效性。试验达到了其主要终点无事件生存期(EFS),与单独放疗相比,接受KEYTRUDA联合标准放疗治疗的患者显示出统计学上显著的改善。 KEYNOTE-689试 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
BP endorses Trump
Calls for cognitive test
GOP ad mistake in MI
Medicare open enrollment
Human smell study
FEMA pauses aid in NC
Files for bankruptcy
Urged to reverse trans ban
MA town fines resident
COVID linked to diabetes?
Arrests at the NYSE
Harbaugh’s heart scare
Approves mpox vaccine
Europa Clipper launches
Rally suspect denies plot
FL power to be restored
Ethel Kennedy’s funeral
On their way to DC
Game Freak data breach
Hezbollah drone attack
Fed’s Kashkari on rate cuts
Tech founder's murder trial
Hit with new civil lawsuits
Indigenous Peoples Day
Rapper Ka dies at 52
Campaign events in PA
2,471-pound pumpkin wins
EU trial about funds
Detroit off-duty officer killed
BCBS settles antitrust claims
反馈